This enduring dialogue between a physician and PA aims to improve oncology clinicians competence in optimizing antibody-drug conjugate (ADC) therapy for previously treated gynecologic cancers through effective, patient-centered management of adverse events. Learners have access to downloadable materials and a clinical practice tool for use in practice.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 27 Trinity Place, Suite 185
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedSep 25, 2026
-
Last day to claim creditSep 25, 2027 12 months left
-
PRIME Education, Inc. (PRIME®) Transforming Care in Endometrial Cancer: The Rise of Antibody-Drug Conjugates
-
Learner’s Digest International (TM) Management of Breast Cancer
-
Efficient CME, CME Outfitters, LLC Time-Out! Troubleshooting Evolving Situations Related to the Integration of Novel Antibody Drug Conjugates into the Management of HER2-Positive Early Breast Cancer
-
Answers in CME Inc. (AiCME) Navigating ADC Therapy in Lung Cancer: An APP Guide to Selection, Safety, and Care Coordination
-
Answers in CME Inc. (AiCME) Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer
-
Answers in CME Inc. (AiCME) Rapid Roundup 2025 in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care
